PERSON DIRECTORY
Peter Kolchinsky
Peter Kolchinsky appears in 1 indexed conversation across Biotech Hangout. This directory brings every appearance, source, TL;DR, digest, and transcript into one searchable feed.
Episode 140 - May 2, 2025
Eric SchmidtSam FazeliAdam FeuersteinPeter Kolchinsky
Biotech’s three-week XBI rebound is supported by strong launches, better-than-feared earnings and returning deals, but panelists viewed it as stabilization while FDA disruption, vaccine policy and tariffs continue to discount the sector.BridgeBio’s Attruby highlights commercial execution, while Summit’s ivonescimab—with a 0.77 preliminary overall-survival hazard ratio versus Keytruda—faces pivotal midyear U.S.HARMONi validation; transparency and franchise risks remain visible across the sector.